UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab

Journal of Crohn's and colitis, 2016-12, Vol.10 (12), p.1437-1444

2016

Volltextzugriff (PDF)

A Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Vedolizumab

Clinical pharmacokinetics, 2017-11, Vol.56 (11), p.1287-1301

2017

Volltextzugriff (PDF)

Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis

The New England journal of medicine, 2013-08, Vol.369 (8), p.699-710

2013

Volltextzugriff (PDF)

Vedolizumab for the treatment of active ulcerative colitis: A randomized controlled phase 2 dose‐ranging study

Inflammatory bowel diseases, 2012-08, Vol.18 (8), p.1470-1479

2012

Volltextzugriff (PDF)

In vitro assessment of the effects of vedolizumab binding on peripheral blood lymphocytes

mAbs, 2013-11, Vol.5 (6), p.842-850

2013

Volltextzugriff (PDF)

Effect of CC Chemokine Receptor 2 CCR2 Blockade on Serum C-Reactive Protein in Individuals at Atherosclerotic Risk and With a Single Nucleotide Polymorphism of the Monocyte Chemoattractant Protein-1 Promoter Region

The American journal of cardiology, 2011-03, Vol.107 (6), p.906-911

2011

Volltextzugriff (PDF)

A monomethyl auristatin E-conjugated antibody to guanylyl cyclase C is cytotoxic to target-expressing cells in vitro and in vivo

PloS one, 2018-01, Vol.13 (1), p.e0191046-e0191046

2018

Volltextzugriff (PDF)

Why CCR2 and CCR5 blockade failed and why CCR1 blockade might still be effective in the treatment of rheumatoid arthritis

PloS one, 2011-07, Vol.6 (7), p.e21772

2011

Volltextzugriff (PDF)

Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results

Gut, 2015-01, Vol.64 (1), p.77-83

2015

Volltextzugriff (PDF)

Tu1742 – Long-Term Immunogenicity of Intravenous Vedolizumab in Ulcerative Colitis and Crohn's Disease (Gemini Program)

Gastroenterology (New York, N.Y. 1943), 2019-05, Vol.156 (6), p.S-1107-S-1107

2019

Volltextzugriff (PDF)

Vedolizumab, a monoclonal antibody to the gut homing α4β7 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotype

Journal of neuroimmunology, 2013-11, Vol.264 (1), p.123-126

2013

Volltextzugriff (PDF)

Exclusive antagonism of the α4β7 integrin by vedolizumab confirms the gut‐selectivity of this pathway in primates

Inflammatory bowel diseases, 2012-11, Vol.18 (11), p.2107-2119

2012

Volltextzugriff (PDF)

Trial in progress: A phase 1-2, first-in-human, open label, dose escalation and expansion study of AU-007, a monoclonal antibody that binds to IL-2 and inhibits IL-2Rα binding, in patients with advanced solid tumors

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS2671-TPS2671

2022

Volltextzugriff (PDF)

Development and validation of receptor occupancy pharmacodynamic assays used in the clinical development of the monoclonal antibody vedolizumab

Cytometry. Part B, Clinical cytometry, 2016-03, Vol.90 (2), p.168-176

2016

Volltextzugriff (PDF)

Fecal Calprotectin Responses Following Induction Therapy With Vedolizumab in Moderate to Severe Ulcerative Colitis: A Post Hoc Analysis of GEMINI 1

Inflammatory bowel diseases, 2019-03, Vol.25 (4), p.803-810

2019

Volltextzugriff (PDF)

Phase I Study of the Investigational Anti-Guanylyl Cyclase Antibody-Drug Conjugate TAK-264 (MLN0264) in Adult Patients with Advanced Gastrointestinal Malignancies

Clinical cancer research, 2016-10, Vol.22 (20), p.5049-5057

2016

Volltextzugriff (PDF)

Antagonizing the α4β1 integrin, but not α4β7, inhibits leukocytic infiltration of the central nervous system in rhesus monkey experimental autoimmune encephalomyelitis

The Journal of immunology (1950), 2013-03, Vol.190 (5), p.1961-1973

2013

Volltextzugriff (PDF)

Internalization of the vedolizumab/α4β7 complex and kinetics of restoring functional activity: P-238

Inflammatory bowel diseases, 2011-12, Vol.17, p.S82-S83

2011

Volltextzugriff (PDF)

Phase I Study of the Investigational Anti-Guanylyl Cyclase AntibodyDrug Conjugate TAK-264 (MLN0264) in Adult Patients with Advanced Gastrointestinal Malignancies

Clinical cancer research, 2016-10, Vol.22 (20), p.5049-5057

2016

Volltextzugriff (PDF)

Vedolizumab Does Not Affect the Suppressive Activity of Gut-homing T Regulatory Cells: P-177

Inflammatory bowel diseases, 2012-12, Vol.18, p.S86-S87

2012

Volltextzugriff (PDF)

Abstract PR12: MLN0264, an investigational, first-in-class antibody-drug conjugate (ADC) targeting guanylyl cyclase C (GCC), demonstrates antitumor activity alone and in combination with gemcitabine in human pancreatic cancer xenograft models expressing GCC

Molecular cancer therapeutics, 2013-11, Vol.12 (11_Supplement), p.PR12-PR12

2013

Volltextzugriff (PDF)

Tu1955 Fecal Calprotectin Reductions in Patients With Mucosal Healing During Vedolizumab Induction Therapy in GEMINI 1

Gastroenterology (New York, N.Y. 1943), 2016-04, Vol.150 (4), p.S989-S989

2016

Volltextzugriff (PDF)

512 Association of Vedolizumab Drug Concentrations at or Before Week 6 With Remission at Week 14 in Moderately to Severely Active Ulcerative Colitis Patients From GEMINI 1

Gastroenterology (New York, N.Y. 1943), 2016-04, Vol.150 (4), p.S105-S105

2016

Volltextzugriff (PDF)

P-140 Pharmacokinetic/Pharmacodynamic Relationship and Immunogenicity of Vedolizumab in Adults with Inflammatory Bowel Disease: Additional Results from GEMINI 1 and 2

Inflammatory bowel diseases, 2013-12, Vol.19, p.S80

2013

Volltextzugriff (PDF)

Vedolizumab Induces Clinical Response and Remission Across a Range of Baseline Fecal Calprotectin Levels in Patients with Ulcerative Colitis: Results from GEMINI 1: 1638

The American journal of gastroenterology, 2014-10, Vol.109, p.S486

2014

Volltextzugriff (PDF)

1 – 25 von 54

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(49)
Mit Volltextzugriff
(48)

Publikationsform

Sprache

Englisch
(54)
Japanisch
(8)

Erscheinungsjahr

n.n

Thema

Humans
(20)
Science & Technology
(20)
Life Sciences & Biomedicine
(15)
Male
(12)
Female
(10)
Adult
(8)
Aged
(7)
Middle Aged
(7)
Vedolizumab
(7)
Colitis, Ulcerative - Drug Therapy
(6)
Inflammatory Bowel Disease
(6)
Animals
(5)
Antibodies, Monoclonal, Humanized - Pharmacology
(5)
Antibodies, Monoclonal, Humanized - Therapeutic Use
(5)
Gastroenterology & Hepatology
(5)
Young Adult
(5)
Double-Blind Method
(4)
Multidisciplinary Sciences
(4)
Proteins
(4)
Science & Technology - Other Topics
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab

A Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Vedolizumab

Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis

Vedolizumab for the treatment of active ulcerative colitis: A randomized controlled phase 2 dose‐ranging study

In vitro assessment of the effects of vedolizumab binding on peripheral blood lymphocytes

Effect of CC Chemokine Receptor 2 CCR2 Blockade on Serum C-Reactive Protein in Individuals at Atherosclerotic Risk and With a Single Nucleotide Polymorphism of the Monocyte Chemoattractant Protein-1 Promoter Region

A monomethyl auristatin E-conjugated antibody to guanylyl cyclase C is cytotoxic to target-expressing cells in vitro and in vivo

Why CCR2 and CCR5 blockade failed and why CCR1 blockade might still be effective in the treatment of rheumatoid arthritis

Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results

Tu1742 – Long-Term Immunogenicity of Intravenous Vedolizumab in Ulcerative Colitis and Crohn's Disease (Gemini Program)

Vedolizumab, a monoclonal antibody to the gut homing α4β7 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotype

Exclusive antagonism of the α4β7 integrin by vedolizumab confirms the gut‐selectivity of this pathway in primates

Trial in progress: A phase 1-2, first-in-human, open label, dose escalation and expansion study of AU-007, a monoclonal antibody that binds to IL-2 and inhibits IL-2Rα binding, in patients with advanced solid tumors

Development and validation of receptor occupancy pharmacodynamic assays used in the clinical development of the monoclonal antibody vedolizumab

Fecal Calprotectin Responses Following Induction Therapy With Vedolizumab in Moderate to Severe Ulcerative Colitis: A Post Hoc Analysis of GEMINI 1

Phase I Study of the Investigational Anti-Guanylyl Cyclase Antibody-Drug Conjugate TAK-264 (MLN0264) in Adult Patients with Advanced Gastrointestinal Malignancies

Antagonizing the α4β1 integrin, but not α4β7, inhibits leukocytic infiltration of the central nervous system in rhesus monkey experimental autoimmune encephalomyelitis

Internalization of the vedolizumab/α4β7 complex and kinetics of restoring functional activity: P-238

Phase I Study of the Investigational Anti-Guanylyl Cyclase AntibodyDrug Conjugate TAK-264 (MLN0264) in Adult Patients with Advanced Gastrointestinal Malignancies

Vedolizumab Does Not Affect the Suppressive Activity of Gut-homing T Regulatory Cells: P-177

Abstract PR12: MLN0264, an investigational, first-in-class antibody-drug conjugate (ADC) targeting guanylyl cyclase C (GCC), demonstrates antitumor activity alone and in combination with gemcitabine in human pancreatic cancer xenograft models expressing GCC

Tu1955 Fecal Calprotectin Reductions in Patients With Mucosal Healing During Vedolizumab Induction Therapy in GEMINI 1

512 Association of Vedolizumab Drug Concentrations at or Before Week 6 With Remission at Week 14 in Moderately to Severely Active Ulcerative Colitis Patients From GEMINI 1

P-140 Pharmacokinetic/Pharmacodynamic Relationship and Immunogenicity of Vedolizumab in Adults with Inflammatory Bowel Disease: Additional Results from GEMINI 1 and 2

Vedolizumab Induces Clinical Response and Remission Across a Range of Baseline Fecal Calprotectin Levels in Patients with Ulcerative Colitis: Results from GEMINI 1: 1638

Suchergebnisse filtern